"Evidence indicates that in people with idiopathic Parkinson’s, [...] the LRRK2 protein is overly active, regardless of [...] whether or not they have a mutated LRRK2."
"Molecules that block the activity of the LRRK2 kinase [...] are currently being tested in clinical trials."
parkinsonsnewstoday.com/201...
Research paper: LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease (2019)